Making sure patients continue to get the medicines they need is of upmost importance as we negotiate the UK’s withdrawal from the EU.
The ABPI is delighted to announce the appointment of Professor Carole Longson MBE as Chief Scientific Officer at the Association of the British Pharmaceutical Industry (ABPI). Carole joins the ABPI from her current role as Executive Director and Board Member at the National Institute for Health and...
As the new AMR Industry Alliance launches its first progress report, ABPI chief executive Mike Thompson welcome the industry’s willingness to work collaboratively to detect, prevent and control AMR.
As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.
This week, the House of Lords Science and Technology Committee published a report into the Life Sciences Industrial Strategy, asking: "Who's Driving the Bus?"
Mike Thompson, chief executive of the ABPI, opening address to the ABPI Annual Conference outlining the strength of the industry and looking ahead to the next 70 years.
ABPI’s Disclosure UK shows the pharmaceutical industry continues to invest in UK R&D:
The Court has today made a judgment on the use of Avastin to treat a condition called wet age-related macular degeneration (wet AMD).
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
Lisa Anson, President of the ABPI, closing remarks to the ABPI Annual Conference on the future of UK life sciences.